Profound Medical Management
Management criteria checks 3/4
Profound Medical's CEO is Arun Menawat, appointed in Aug 2016, has a tenure of 7.83 years. total yearly compensation is $889.95K, comprised of 41.6% salary and 58.4% bonuses, including company stock and options. directly owns 1.89% of the company’s shares, worth CA$5.59M. The average tenure of the management team and the board of directors is 1.8 years and 4.8 years respectively.
Key information
Arun Menawat
Chief executive officer
US$889.9k
Total compensation
| CEO salary percentage | 41.6% |
| CEO tenure | 7.8yrs |
| CEO ownership | 1.9% |
| Management average tenure | 1.8yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Does Profound Medical (TSE:PRN) Have A Healthy Balance Sheet?
May 03
Is Profound Medical (TSE:PRN) Using Debt In A Risky Way?
Sep 15Will Profound Medical (TSE:PRN) Spend Its Cash Wisely?
Sep 07Here's Why We're Not Too Worried About Profound Medical's (TSE:PRN) Cash Burn Situation
Jan 07We Think Profound Medical (TSE:PRN) Can Easily Afford To Drive Business Growth
Jul 02We Take A Look At Why Profound Medical Corp.'s (TSE:PRN) CEO Compensation Is Well Earned
May 13Analysts Expect Breakeven For Profound Medical Corp. (TSE:PRN) Before Long
May 07We Think Profound Medical (TSE:PRN) Can Afford To Drive Business Growth
Mar 25How Many Profound Medical Corp. (TSE:PRN) Shares Do Institutions Own?
Mar 04Profound Medical Corp. (TSE:PRN) Is Expected To Breakeven In The Near Future
Jan 27
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$28m |
| Dec 31 2023 | US$890k | US$370k | -US$29m |
| Sep 30 2023 | n/a | n/a | -US$29m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$27m |
| Dec 31 2022 | US$916k | US$344k | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$29m |
| Jun 30 2022 | n/a | n/a | -US$30m |
| Mar 31 2022 | n/a | n/a | -US$31m |
| Dec 31 2021 | US$4m | US$481k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$28m |
| Mar 31 2021 | n/a | n/a | -US$26m |
| Dec 31 2020 | US$2m | US$1m | -US$22m |
| Sep 30 2020 | n/a | n/a | -US$18m |
| Jun 30 2020 | n/a | n/a | -US$17m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$2m | US$531k | -US$15m |
| Sep 30 2019 | n/a | n/a | -US$15m |
| Jun 30 2019 | n/a | n/a | -US$14m |
| Mar 31 2019 | n/a | n/a | -US$14m |
| Dec 31 2018 | US$672k | US$509k | -US$15m |
| Sep 30 2018 | n/a | n/a | -US$16m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$15m |
| Dec 31 2017 | US$264k | US$264k | -US$15m |
Compensation vs Market: Arun's total compensation ($USD889.95K) is about average for companies of similar size in the Canadian market ($USD783.70K).
Compensation vs Earnings: Arun's compensation has been consistent with company performance over the past year.
CEO
Arun Menawat (69 yo)
7.8yrs
Tenure
US$889,948
Compensation
Dr. Arun Swarup Menawat, Ph D., MBA, served as the Chairman at Firefly Neuroscience, Inc. and is its Director. He serves as the Chairman at Profound Medical Corp. Dr. Menawat has been the Chief Executive O...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 7.8yrs | US$889.95k | 1.89% $ 5.6m | |
| Chief Financial Officer | 3.1yrs | US$669.26k | 0.097% $ 287.1k | |
| Chief Operating Officer | less than a year | US$396.81k | 0.055% $ 163.8k | |
| Senior Vice President for Strategic Alliances | 1.8yrs | US$226.17k | 0.0039% $ 11.5k | |
| Chief Commercial Officer of Global | 1.8yrs | US$555.98k | 0% $ 0 | |
| Investor Relations | no data | no data | no data | |
| VP of International Sales & Marketing | no data | no data | no data | |
| Assistant Corporate Controller | no data | no data | no data | |
| Software Developer | no data | no data | no data |
1.8yrs
Average Tenure
53.5yo
Average Age
Experienced Management: PRN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 9yrs | US$889.95k | 1.89% $ 5.6m | |
| Independent Director | 6yrs | US$101.96k | 0.071% $ 209.2k | |
| Independent Lead Director | 6yrs | US$102.91k | 0.28% $ 822.1k | |
| Independent Director | 3.3yrs | US$97.91k | 0.025% $ 72.5k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 3.6yrs | US$100.41k | 0.013% $ 38.1k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | 1.7yrs | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data |
4.8yrs
Average Tenure
67yo
Average Age
Experienced Board: PRN's board of directors are considered experienced (4.8 years average tenure).